Tarsus Pharmaceuticals, Inc.

Biological Products, (No Diagnostic Substances)

TARS Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001819790 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$3.71B
43,882,996 shares Covers every share class this company has on file.
Insiders on file
12
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$125.60M
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
3.38%
insider-held value divided by market capitalisation

What Tarsus Pharmaceuticals, Inc. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$451.36M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$66.00M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
370
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at Tarsus Pharmaceuticals, Inc.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against Tarsus Pharmaceuticals, Inc..
Insider Reported role Shares Value Last action
Officers 5
Seshadri Neervannan COO 83,266 $7.56M S Open-market sale Sep 4, 2026 position reported
Bryan Wahl General Counsel 63,959 $5.81M S Open-market sale Mar 19, 2026 position reported
Aziz Mottiwala Other Executive 61,480 $5.58M S Open-market sale Mar 19, 2026 position reported
Jeffrey S Farrow Executive 43,316 $3.93M S Open-market sale Jun 16, 2026 position reported
Dianne C Whitfield Other Executive 35,028 $3.18M S Open-market sale Mar 19, 2026 position reported
Officers who also sit on the board 2
Bobak R Azamian CEO 891,412 $80.92M S Open-market sale Sep 4, 2026 position reported
Elizabeth Yeu Lin Other Executive 41,708 $3.79M S Open-market sale Sep 4, 2026 position reported
Directors 5
William J. Link Ph.D. Board Member 116,332 $10.56M S Open-market sale Jun 15, 2026 position reported
Andrew D Goldberg Board Member 16,700 $1.52M M Option exercise or conversion Jun 12, 2026 position reported
Wendy L. Yarno Board Member 13,700 $1.24M M Option exercise or conversion Jun 12, 2026 position reported
Bhaskar Chaudhuri Board Member 8,700 $789.8K M Option exercise or conversion Jun 12, 2026 position reported
David E. I. Pyott Board Member 7,991 $725.4K M Option exercise or conversion Apr 24, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

Elizabeth Yeu Lin sold 10,773 Tarsus Pharmaceuticals, Inc. (TARS) shares for $942,635 on Sep 4, 2026

Unusual change in a direct holding

Flagged because the change that day in the shares this person holds directly was unusually large compared with their own earlier changes. The rows below are the open-market trades reported that day; under each share count is the balance the filing reports after that line.

Elizabeth Yeu Lin sold 10,773 Tarsus Pharmaceuticals, Inc. (TARS) shares for $942,635 on Sep 4, 2026
Date Insider Transaction Shares Price Value Filing
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 5,387 held after: 7,933 $85.00 $457,895 SEC filing ↗
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 5,386 held after: 2,547 $90.00 $484,740 SEC filing ↗

Total of the rows above: $942,635, in the currency the filings report.

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Elizabeth Yeu Lin sold 5,387 Tarsus Pharmaceuticals, Inc. (TARS) shares for $430,960 on Sep 2, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Elizabeth Yeu Lin sold 5,387 Tarsus Pharmaceuticals, Inc. (TARS) shares for $430,960 on Sep 2, 2026
Date Insider Transaction Shares Price Value Filing
Sep 2, 2026 Elizabeth Yeu Lin S Open-market sale 5,387 held after: 13,320 $80.00 $430,960 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Elizabeth Yeu Lin sold 4,601 Tarsus Pharmaceuticals, Inc. (TARS) shares for $339,830 on Sep 1, 2026

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Elizabeth Yeu Lin sold 4,601 Tarsus Pharmaceuticals, Inc. (TARS) shares for $339,830 on Sep 1, 2026
Date Insider Transaction Shares Price Value Filing
Sep 1, 2026 Elizabeth Yeu Lin S Open-market sale 4,601 held after: 18,707 $73.86 $339,830 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 123 rows we hold, 0 are open-market purchases and 83 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for Tarsus Pharmaceuticals, Inc., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 1,590 $90.00 $143.1K SEC filing ↗
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 1,590 $85.00 $135.2K SEC filing ↗
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 5,386 $90.00 $484.7K SEC filing ↗
Sep 4, 2026 Elizabeth Yeu Lin S Open-market sale 5,387 $85.00 $457.9K SEC filing ↗
Sep 4, 2026 Bobak R Azamian S Open-market sale 2,900 $91.27 $264.7K SEC filing ↗
Sep 4, 2026 Bobak R Azamian S Open-market sale 7,100 $90.27 $640.9K SEC filing ↗
Sep 4, 2026 Seshadri Neervannan S Open-market sale 4,564 $85.00 $387.9K SEC filing ↗
Sep 2, 2026 Elizabeth Yeu Lin S Open-market sale 1,590 $80.00 $127.2K SEC filing ↗
Sep 2, 2026 Elizabeth Yeu Lin S Open-market sale 5,387 $80.00 $431.0K SEC filing ↗
Sep 2, 2026 Bobak R Azamian S Open-market sale 10,000 $80.06 $800.6K SEC filing ↗
Sep 1, 2026 Elizabeth Yeu Lin S Open-market sale 4,601 $73.86 $339.8K SEC filing ↗
Jun 17, 2026 Bobak R Azamian S Open-market sale 5,418 $61.81 $334.9K SEC filing ↗
Jun 17, 2026 Bobak R Azamian S Open-market sale 4,582 $61.24 $280.6K SEC filing ↗
Jun 16, 2026 Jeffrey S Farrow S Open-market sale 14,396 $60.95 $877.4K SEC filing ↗
Jun 15, 2026 Jeffrey S Farrow M Option exercise or conversion 27,881 $0.00 $0 SEC filing ↗
Jun 15, 2026 William J. Link Ph.D. S Open-market sale 1,928 $62.94 $121.3K SEC filing ↗
Jun 15, 2026 William J. Link Ph.D. S Open-market sale 10,572 $61.97 $655.1K SEC filing ↗
Jun 12, 2026 Andrew D Goldberg M Option exercise or conversion 2,954 $0.00 $0 SEC filing ↗
Jun 12, 2026 Bhaskar Chaudhuri M Option exercise or conversion 2,954 $0.00 $0 SEC filing ↗
Jun 12, 2026 William J. Link Ph.D. M Option exercise or conversion 2,954 $0.00 $0 SEC filing ↗
Jun 12, 2026 Wendy L. Yarno M Option exercise or conversion 2,954 $0.00 $0 SEC filing ↗
Apr 24, 2026 David E. I. Pyott M Option exercise or conversion 1,383 $0.00 $0 SEC filing ↗
Mar 20, 2026 Seshadri Neervannan S Open-market sale 2,989 $66.75 $199.5K SEC filing ↗
Mar 19, 2026 Elizabeth Yeu Lin S Open-market sale 390 $67.00 $26.1K SEC filing ↗
Mar 19, 2026 Dianne C Whitfield S Open-market sale 4,174 $67.00 $279.7K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from Tarsus Pharmaceuticals, Inc.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from Tarsus Pharmaceuticals, Inc.’s own SEC filings multiplied by the closing price we hold for the same stock.